CBT-006

Cloudbreak Therapeutics, LLC · Phase 2 active Small molecule

At a glance

Generic name	CBT-006
Also known as	not apply
Sponsor	Cloudbreak Therapeutics, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CBT-006 CI brief — competitive landscape report
CBT-006 updates RSS · CI watch RSS
Cloudbreak Therapeutics, LLC portfolio CI